

## Product datasheet for **TR512649**

### Mapk12 Mouse shRNA Plasmid (Locus ID 29857)

#### Product data:

|                           |  |
|---------------------------|--|
| Product Type:             | shRNA Plasmids   |
| Product Name:             | Mapk12 Mouse shRNA Plasmid (Locus ID 29857)  |
| Locus ID:                 | 29857  |
| Synonyms:                 | AW123708; Erk6; P38gamma; Prkm12; Sapk3  |
| Vector:                   | pRS (TR20003)  |
| E. coli Selection:        | Ampicillin   |
| Mammalian Cell Selection: | Puromycin  |
| Format:                   | Retroviral plasmids  |
| Components:               | Mapk12 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 29857). 5µg purified plasmid DNA per construct<br>29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq:                   | <a href="#">BC021640</a> , <a href="#">NM_013871</a> , <a href="#">NM_013871.1</a> , <a href="#">NM_013871.2</a> , <a href="#">NM_013871.3</a> , <a href="#">BC002134</a>  |
| UniProt ID:               | <a href="#">O08911</a>   |



[View online »](#)

**Summary:**

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in myoblast differentiation and also in the down-regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation. Phosphorylates DLG1. Following osmotic shock, MAPK12 in the cell nucleus increases its association with nuclear DLG1, thereby causing dissociation of DLG1-SFPQ complexes. This function is independent of its catalytic activity and could affect mRNA processing and/or gene transcription to aid cell adaptation to osmolarity changes in the environment. Regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage and G2 arrest after gamma-radiation exposure. MAPK12 is involved in the regulation of SLC2A1 expression and basal glucose uptake in L6 myotubes; and negatively regulates SLC2A4 expression and contraction-mediated glucose uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is stimulated by MAPK14 and inhibited by MAPK12, leading to a distinct AP-1 regulation. MAPK12 is required for the normal kinetochore localization of PLK1, prevents chromosomal instability and supports mitotic cell viability. MAPK12-signaling is also positively regulating the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration. [UniProtKB/Swiss-Prot Function]

**shRNA Design:**

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact [techsupport@origene.com](mailto:techsupport@origene.com). If you need a special design or shRNA sequence, please utilize our [custom shRNA service](#).

**Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).